BEIGF (BeOne Medicines) Tax Provision: $-212 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BEIGF BeOne Medicines Ltd BEIGF
79 GF Score
Price $21.95
GF Value $22.98
! 5 Warning Signs
View Full Analysis

What is BeOne Medicines Tax Provision?

BeOne Medicines BEIGF 79 Tax Provision is $-212 Mil as of Jun. 2026. GuruFocus rates BEIGF with a GF Score™ of 79/100 and a GF Value™ of $22.98. The stock has 5 warning signs investors should review.

BeOne Medicines's tax provision for the three months ended in Jun. 2026 was $-75 Mil. Its tax provision for the trailing twelve months (TTM) ended in Jun. 2026 was $-212 Mil.

BeOne Medicines Tax Provision Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines Tax Provision Chart

BeOne Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19.23 -42.78 -55.87 -111.79 -129.92

BeOne Medicines Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.23 -22.32 -82.74 -31.86 -75.45
BEIGF
79GF Score
BeOne Medicines Ltd BEIGF
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeOne Medicines Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-212 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of $-212 Mil mean?
BeOne Medicines (BEIGF) has a Tax Provision of $-212 Mil as of Jun. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on BeOne Medicines and its competitors.
Is BeOne Medicines' Tax Provision too high?
BeOne Medicines' current Tax Provision is $-212 Mil. Overall, BeOne Medicines has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Tax Provision compare to ALNY and RVMD?
BeOne Medicines' Tax Provision of $-212 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current Tax Provision is $-212 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
BeOne Medicines (BEIGF) has a current Tax Provision of $-212 Mil. The stock's GF Value™ is $22.98, compared to a current price of $21.95 — trading 4.5% below its estimated fair value. The current Tax Provision is $-212 Mil. BeOne Medicines' overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For BeOne Medicines (BEIGF), the current Tax Provision is $-212 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (BEIGF) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of $21.95 is trading 4.5% below its estimated GF Value™ of $22.98.

Key valuation signals for BEIGF:

  • Tax Provision: $-212 Mil
  • GF Value™: $22.98 vs. price of $21.95 (4.5% below fair value)
  • GF Score™: 79/100 with 5 warning signs

No single metric tells the full story. See the BEIGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
79GF Score

Get the complete analysis for BEIGF

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.95
Price
$22.98
GF Value